ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2738 • 2018 ACR/ARHP Annual Meeting

    A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    Peter A. Merkel1, David Jayne2, Thomas J. Schall3, Pirow Bekker3 and Jan Hillson3, 1Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 3ChemoCentryx, Mountain View, CA

    A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPeter A. Merkel1, David…
  • Abstract Number: 2739 • 2018 ACR/ARHP Annual Meeting

    Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events

    Luciano Fernando Lo Giudice1, Marina Scolnik2, Jose Maximiliano Martinez P3, Aurelia Luissi1, Valeria Scaglioni2 and Enrique R Soriano2, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, 2Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, 3Rheumatology, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: The glucocorticoid toxicity index (GTI) (Miloslavsky et al. Ann Rheum Dis 2017) is useful to assess impact on morbility associated with these drugs. It…
  • Abstract Number: 2740 • 2018 ACR/ARHP Annual Meeting

    Clinical and Laboratory Characteristics of ANCA-Associated Vasculitis in Pediatric and Young Adult Patients: A Retrospective Review

    Melissa Swee1, Manish Suneja2, Mandeep Gill3 and Bharat Kumar4, 1Transplant Nephrology, University of Iowa, Iowa City, IA, 2Internal Medicine, University of Iowa, Iowa City, IA, 3Division of Nephrology, University of Iowa Hospitals and Clinics, Iowa City, IA, 4Internal Medicine-Division of Immunology, University of Iowa, Iowa City, IA

    Background/Purpose: ANCA-associated vasculitis (AAV) is a heterogenous group of small-vessel vasculitides that typically affects the kidneys, respiratory tract, and other organ systems. The onset of…
  • Abstract Number: 2741 • 2018 ACR/ARHP Annual Meeting

    Candidate Biomarkers in ANCA-Associated Vasculitis Identified Using a Proteomic Approach

    Paul A. Monach1, Hemang Parikh2, Laurie Conklin3, Jesse Damsker4, Peter C. Grayson5, David Cuthbertson6, Simon Carette7, Nader A. Khalidi8, Curry L. Koening9, Carol Langford10, Carol A. McAlear11, Larry W. Moreland12, Christian Pagnoux13, Philip Seo14, Ulrich Specks15, Antoine G. Sreih16, Steven R. Ytterberg17, Eric Hoffman4 and Peter A. Merkel18, 1Rheumatology, VA Boston Healthcare System, Boston, MA, 2University of South Florida, Tampa, FL, 3ReveraGen BioPharma, Rockville, MD, 4ReveraGen Biopharma, Rockville, MD, 5National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, 6Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 7Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 8Rheumatology, McMaster University, Hamilton, ON, Canada, 9Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, 10Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 11Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, 12Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 13Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 14Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 15Mayo Clinic College of Medicine, Rochester, MN, 16Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 17Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 18Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Concentrations of many circulating proteins are elevated during severe, active ANCA-associated vasculitis (AAV). Finding biomarkers associated with milder disease, a more clinically relevant need,…
  • Abstract Number: 2742 • 2018 ACR/ARHP Annual Meeting

    Rituximab Versus Cyclophosphamide for Vasculitic Neuropathy: A Patient Reported Outcomes Study

    Aditi Patel1, Kevin Byram2, Yuxuan Jin3, Alexander Wu1, Yuebing Li4, Leonard H. Calabrese5 and Rula A Hajj-Ali6, 1Internal Medicine, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Department of Neurology, Cleveland Clinic, Cleveland, OH, 5Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 6Rheumatic and Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Vasculitic neuropathy (VN) is a major complication of systemic vasculitis and contributes to morbidity, functional limitation, and health care utilization in affected patients. Patient…
  • Abstract Number: 2743 • 2018 ACR/ARHP Annual Meeting

    Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation

    Yusuke Miyazaki1, Shingo Nakayamada1, Satoshi Kubo1, Kazuhisa Nakano1, Shigeru Iwata2, Shunsuke Fukuyo3, Akio Kawabe4 and Yoshiya Tanaka5, 1First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3University of Occupational and Environmental Health, Japan, Fukuoka, Japan, 4University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, 5University of Occupational and Environmental Health, Kitakyushu, Japan

    Background/Purpose: B cell depletion by rituximab (RTX)is effective treatment for ANCA-associated vasculitis (AAV). However, the phenotype of peripheral B cells and the selection criteria for…
  • Abstract Number: 2744 • 2018 ACR/ARHP Annual Meeting

    Giant-Cell Arteritis: Is Glucocorticoid-Sparing Treatment Still Relevant? a Retrospective Study

    Segolene Perrineau1, Romain Paule2, Pierre Charles3, Martine GAYRAUD4, Benjamin Terrier1,5, Loïc Guillevin1, Luc Mouthon1,5 and Alexis Régent2,5, 1Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Descartes, PARIS, France, 2Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Descartes, Paris, France, 3Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, 4Department of Internal Medicine, Institut Mutualiste Montsouris, PARIS, France, 5Institut Cochin, INSERM U1016, CNRS UMR 8104, PARIS, France

    Background/Purpose: Giant-cell arteritis (GCA) is the most common primary large-vessel vasculitis affecting patients over 50 yr. Despite frequent and severe adverse events (AEs), glucocorticoids (GCs)…
  • Abstract Number: 2745 • 2018 ACR/ARHP Annual Meeting

    Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents

    Daniela Rossi1, Irene Cecchi2, Elena Rubini3, Massimo Radin4, Savino Sciascia5 and Dario Roccatello6, 1Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, 2Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, 4Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 5Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, 6Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy

    Background/Purpose: At least 2 biological therapies [tocilizumab (TCZ) and abatacept (ABA)] have been proven to be effective in the management of Giant cell arteritis (GCA)…
  • Abstract Number: 2746 • 2018 ACR/ARHP Annual Meeting

    Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study

    Shuntaro Saito, Ayumi Okuyama, Yusuke Okada, Akiko Shibata, Ryota Sakai, Kentaro Chino, Takahiko Kurasawa, Tsuneo Kondo, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    Background/Purpose: To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy for Large Vessel Vasculitis (LVV), including Takayasu arteritis (TAK) and Giant cell arteritis (GCA).…
  • Abstract Number: 2747 • 2018 ACR/ARHP Annual Meeting

    Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival

    Stig Tengesdal and Geirmund Myklebust, Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway

    Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are used as adjunct immunosuppressants and corticosteroid sparing agents in treatment of Giant Cell Arteritis (GCA), but the efficacy…
  • Abstract Number: 2748 • 2018 ACR/ARHP Annual Meeting

    Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT

    Diana Prieto Peña1, Javier Loricera2, Monica Calderón Goercke1, Francisco Javier Narváez3, Elena Aurrecoechea4, Ignacio Villa-Blanco5, Santos Castañeda6, Catalina Gómez-Arango7, Noelia Álvarez-Rivas8, Antonio Mera9, Eva Perez Pampín9, Vicente Aldasoro10, Nagore Fernandez-Llanio Cornella11, Maria Concepcion Alvarez de Buergo12, Luisa Marena Rojas Vargas13, Francisca Sivera14, Eva Galindez-Agirregoikoa15, Roser Solans16, Susana Romero-Yuste17, Belén Atienza-Mateo18, José Luis Martín-Varillas18, Isabel Martínez-Rodríguez19, Ignacio Banzo19, Vanesa Calvo-Río18, Natalia Palmou-Fontana18, José Luis Hernández2, Miguel Angel González-Gay18 and Ricardo Blanco18, 1Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 4Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 5Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 6Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 7Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, 8Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, 9Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 10Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, 11Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, 12Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, 13Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, 14Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 15Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, 16Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, 17Hospital de Pontevedra. Spain, Pontevedra, Spain, 18Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 19Nuclear Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis which can involve the aorta and/or its major branches. Tocilizumab (TCZ) seems to be effective in…
  • Abstract Number: 2749 • 2018 ACR/ARHP Annual Meeting

    Clinical and Anatomical Correlation in Patients with Polymyalgia Rheumatica By 18F-FDG PET/TC. Study of 75 Patients from a Single Referral Center

    Diana Prieto Peña1, Monica Calderón Goercke1, Javier Loricera2, Isabel Martínez-Rodríguez3, Ignacio Banzo3, José Luis Martín-Varillas4, Belén Atienza-Mateo4, Vanesa Calvo-Río1, Carmen Gonzalez Vela5, Miguel Angel González-Gay2 and Ricardo Blanco4, 1Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Nuclear Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 5Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by pain and stiffness of the neck, shoulder and pelvic girdles. It can also be accompanied…
  • Abstract Number: 2750 • 2018 ACR/ARHP Annual Meeting

    Utility of Methotrexate in Polymyalgia Rheumatica

    María Laura de la Torre1, Anabella Rodriguez2, Micaela Ana Cosatti3 and Cecilia N. Pisoni4, 1Internal Medicine, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina, 2Internal Medicine, Hospital General de Agudos “Juan A. Fernández”, Buenos Aires, Argentina, 3Internal Medicine, Rheumatology and Immunology, CEMIC, CABA, Argentina, 4Internal Medicine, CEMIC, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina

    Background/Purpose: Polymyalgia rheumatica (PMR) is a frequent inflammatory condition in patients over 50 years old. Nearly 60% of patients experience relapses of the symptoms during…
  • Abstract Number: 2751 • 2018 ACR/ARHP Annual Meeting

    Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial

    John H. Stone1, Katie Tuckwell2, Sophie Dimonaco3, Micki Klearman2, Martin Aringer4, Daniel Blockmans5, Elisabeth Brouwer6, Maria C. Cid7, Bhaskar Dasgupta8, Juergen Rech9, Carlo Salvarani10, Hendrik Schulze-Koops11, Georg Schett12, Robert F. Spiera13, Sebastian H. Unizony14 and Neil Collinson3, 1Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Genentech, Inc., South San Francisco, CA, 3Roche Products Ltd, Welwyn Garden City, United Kingdom, 4Abteilung für Rheumatologie, Dresden, Germany, 5University Hospital Gasthuisberg, Leuven, Belgium, 6University of Groningen University Medical Center, Groningen, Netherlands, 7University of Barcelona, Barcelona, Spain, 8Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 9Universitätsklinikum Erlangen, Erlangen, Germany, 10Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, 11Ludwig-Maximilians-University, Munich, Germany, Munich, Germany, 12Friedrich-Alexander-Universität Erlangen, Nürnberg und Universitätsklinikum Erlangen, Erlangen, Germany, 13Hospital for Special Surgery, New York, NY, 14Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Adding tocilizumab (TCZ) to tapered prednisone treatment for patients (pts) with giant cell arteritis (GCA) leads to improved rates of sustained glucocorticoid-free remission.1 It…
  • Abstract Number: 2752 • 2018 ACR/ARHP Annual Meeting

    Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice

    Monica Calderón Goercke1, Javier Loricera2, Diana Prieto Peña1, Vicente Aldasoro3, Santos Castañeda4, Ignacio Villa-Blanco5, Alicia Humbría6, Clara Moriano Morales7, Susana Romero-Yuste8, Francisco Javier Narváez9, Catalina Gómez-Arango10, Eva Perez Pampín11, Rafael Melero12, Elena Becerra-Fernández13, Marcelino Revenga Martínez14, Noelia Álvarez-Rivas15, Carlos Galisteo16, Francisca Sivera17, Alejandro Olivé-Marqués18, Maria Concepcion Alvarez de Buergo19, Luisa Marena Rojas Vargas20, Carlos Fernandez-Lopez21, Francisco Navarro22, Enrique Raya Álvarez23, Eva Galindez-Agirregoikoa24, Beatriz Arca25, Roser Solans26, Arantxa Conesa27, Cristina Hidalgo-Calleja28, Carlos Vázquez29, Francisco Ortiz-Sanjuán30, Pau Lluch31, Sara Manrique-Arija32, Paloma Vela33, Eugenio De Miguel34, Carmen Torres-Martín35, Juan Carlos Nieto36, Carmen Ordas-Calvo37, Eva Salgado-Pérez38, María Varela-García39, Cristina Luna Gómez40, Francisco J. Toyos Sáenz de Miera41, Nagore Fernandez-Llanio Cornella42, Jose Andrés Román Ivorra43, Antonio García44, Natalia Palmou-Fontana45, Vanesa Calvo-Río45, José Luis Martín-Varillas45, Belén Atienza-Mateo45, Carmen González-Vela46, Alfonso Corrales45, Elena Aurrecoechea47, Raquel Dos Santos48, Angel García-Manzanares13, Norberto Ortego Centeno49, Sabela Fernández50, Montserrat Corteguera35, Miguel Angel González-Gay2, José Luis Hernández2 and Ricardo Blanco45, 1Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, 4Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 5Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 6Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, 7Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, 8Hospital de Pontevedra. Spain, Pontevedra, Spain, 9Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 10Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, 11Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 12Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, 13Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, 14Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, 15Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, 16Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, 17Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 18Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 19Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, 20Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, 21Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, 22Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, 23Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 24Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, 25Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, 26Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, 27Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, 28Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, 29Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, 30Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain, 31Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, 32Medicine, University of Málaga, MÁLAGA, Spain, 33Reumatología, Hospital General Universitario Alicante, Alicante, Spain, 34Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, 35Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, 36Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 37Hospital Cabueñes, Gijón. Spain, Gijón, Spain, 38Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, 39Complejo Hospitalario de Navarra, Navarra, Spain, 40Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, 41Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, 42Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, 43Hospital La Fe. Valencia. Spain, Valencia, Spain, 44Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, 45Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 46Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 47Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 48Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, 49Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 50Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain

    Background/Purpose: Tocilizumab (TCZ) has showed efficacy in randomized clinical trials in Giant cell arteritis (GCA). Data were of selected patients including many GCA of recent…
  • « Previous Page
  • 1
  • …
  • 1185
  • 1186
  • 1187
  • 1188
  • 1189
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology